Remove Hospital Remove Quality of Life Remove Technology
article thumbnail

New Technology Promises to Revolutionize Valvular Heart Disease Care

DAIC

Getty Images milla1cf Mon, 04/01/2024 - 08:21 April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health and other institutions conclude that new technology could soon help doctors slash that number. “We

article thumbnail

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

DAIC

Data from the TRILUMINATE Pivotal trial demonstrated that patients who received TriClip experienced a marked improvement in the severity of their symptoms and quality of life, with benefits sustained at one year. are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S

Tricuspid 105
article thumbnail

HRS 2024: Innovation Meets Reality

DAIC

Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient safety. Infrequently, we see medical technology innovation of a paradigmatic nature that changes the way physicians approach disease states and dramatically improve results.

article thumbnail

Leveraging AI-Enabled Remote Cardiac Monitoring to Improve Cardiovascular Care

DAIC

By enabling the decisive shift from a reactive to a proactive cardiology model, this technology doesnt just improve patient outcomes it is also helping keep cardiovascular care sustainable and affordable. Participating hospitals will collaborate to share challenges and develop solutions through education, conferences, and webinars.

article thumbnail

FDA Expands Indication for Impella Heart Pumps for Pediatric Patients

DAIC

The opportunity to treat the hearts of pediatric patients with our life-supporting technology is incredible and fills us with gratitude," saidSonya Bhavsar, PhD, Senior Director, R&D, ECP & Pediatrics Platform, Heart Recovery, Johnson & Johnson MedTech. with SmartAssist has been expanded as follows: The Impella 5.5

article thumbnail

Study Shows Medtronic ICM Accurately Predicts Risk Thresholds for AFib Patients Using AI

DAIC

ii The DEFINE AFib clinical study enrolled 973 patients using an app-based enrollment feature and characterized the impact of AF burden on patient outcomes and quality of life. By 2030, approximately 12.2 million people in the U.S. will have AF, an irregular and potentially dangerous heart rhythm. Piccini, M.D.,

AFIB 52
article thumbnail

V-Wave to Present Late-Breaking Data from Pivotal RELIEVE-HF Study at American College of Cardiology Annual Scientific Session and Expo

DAIC

"We're pleased to present the RELIEVE-HF data at this year's ACC meeting, as we continue to advance this important technology with the goal of bringing a much-needed treatment option to patients with advanced heart failure, a leading cause of death and hospitalization in the U.S. and worldwide," said Neal Eigler, M.D. , CEO of V-Wave.